Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis.

Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis.
复制标题

使用硫酸乙酰肝素十八糖(18-mer)作为多靶点药物来预防败血症。

DOI:
10.1073/pnas.2209528120
复制
发表时间:
2023-01-24
影响因子:
11.1
通讯作者:
--
中科院分区:
综合性期刊1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

肝素是具有不同大小糖链和硫酸化模式的硫酸化多糖的混合物。作为一种常用的抗凝药物,肝素在动物模型和脓毒症患者中也显示出对脓毒症的保护作用,但肝素在人体临床试验中的益处存在争议。我们的假设是,使用结构均匀的寡糖将提高对脓毒症的疗效,并加强对作用机制的理解。在这里,我们证明了十八糖(18聚体)抑制宿主动物的炎症反应,以实现对脓毒症的保护。这些发现为设计治疗败血症的治疗药物开辟了化学空间。脓毒症是一种致命的综合征,表现为宿主对感染的不受调节的压倒性炎症反应。在这里,我们利用合成硫酸乙酰肝素十八糖(18聚体)的使用,以防止败血症。18-mer不仅抑制细胞外组蛋白H3和高迁移率族蛋白1(HMGB 1)的促炎活性,而且增强载脂蛋白A-I(ApoA-I)的抗炎作用。我们证明,18聚体保护免受败血症相关的损伤,提高盲肠结扎和穿刺小鼠的存活率,并减少内毒素血症小鼠模型中的炎症。18-mer通过与蛋白质的直接相互作用来中和细胞毒性组蛋白-3(H3)。此外,18-mer参与ApoA-I解离HMGB 1和脂多糖的复合物的作用,该复合物是一种导致脓毒症中细胞死亡和组织损伤的毒性复合物。我们的研究提供了强有力的证据,表明18-mer通过靶向多种介质减轻脓毒症中的炎症损伤,将其与具有单一靶点的其他潜在疗法区分开来。
Heparin is a mixture of sulfated polysaccharides with different sizes of sugar chains and sulfation patterns. As a commonly used anticoagulant drug, heparin also displays protection against sepsis in animal models and sepsis patients, but the benefit of heparin in human clinical trials is controversial. Our hypothesis is that using structurally homogeneous oligosaccharides will improve the efficacy against sepsis and enhance the understanding of the mechanism of action. Here, we demonstrate that an octadecasaccharide (18-mer) inhibits the inflammatory responses of the host animals to achieve protection against sepsis. The findings open a chemical space to design therapeutic agents to treat sepsis. Sepsis is a lethal syndrome manifested by an unregulated, overwhelming inflammation from the host in response to infection. Here, we exploit the use of a synthetic heparan sulfate octadecasaccharide (18-mer) to protect against sepsis. The 18-mer not only inhibits the pro-inflammatory activity of extracellular histone H3 and high mobility group box 1 (HMGB1), but also elicits the anti-inflammatory effect from apolipoprotein A-I (ApoA-I). We demonstrate that the 18-mer protects against sepsis-related injury and improves survival in cecal ligation and puncture mice and reduces inflammation in an endotoxemia mouse model. The 18-mer neutralizes the cytotoxic histone-3 (H3) through direct interaction with the protein. Furthermore, the 18-mer enlists the actions of ApoA-I to dissociate the complex of HMGB1 and lipopolysaccharide, a toxic complex contributing to cell death and tissue damage in sepsis. Our study provides strong evidence that the 18-mer mitigates inflammatory damage in sepsis by targeting numerous mediators, setting it apart from other potential therapies with a single target.
DOI: 10.3390/biomedicines8110503
发表时间: 2020-11-16
期刊: Biomedicines
影响因子: 4.7
作者:
Arnold K;Liao YE;Liu J
通讯作者: Liu J
DOI: 10.1126/scisignal.aaa2581
发表时间: 2015-08-11
期刊: Science signaling
影响因子: 7.3
作者:
Galvani S;Sanson M;Blaho VA;Swendeman SL;Obinata H;Conger H;Dahlbäck B;Kono M;Proia RL;Smith JD;Hla T
通讯作者: Hla T
败血症中的HDL - 危险因素和治疗方法。
DOI: 10.3389/fphar.2015.00244
发表时间: 2015
影响因子: 5.6
作者:
Morin EE;Guo L;Schwendeman A;Li XA
通讯作者: Li XA
DOI: 10.1074/jbc.m112.390161
发表时间: 2012-10-05
影响因子: 4.8
作者:
Peterson, Sherket;Liu, Jian
通讯作者: Liu, Jian
DOI: 10.1182/blood-2012-03-417139
发表时间: 2012-08-23
期刊: BLOOD
影响因子: 20.3
作者:
Axelsson, Jakob;Xu, Ding;Esko, Jeffrey D.
通讯作者: Esko, Jeffrey D.